【Neurelis-Product NRL-1】Neurelis Announces Rapid and Broad Payer Coverage of the Company’s Flagship Product, VALTOCO(Diazepam Nasal Spray)

Partner News

08th June 2020 – Neurelis, Inc.
issued an announcement, which is summarized as follows

More than 176
million lives in the U.S. now covered by payers/managed care/insurance plans
within months of FDA approval of VALTOCO, the first and only nasal spray
treatment of seizure clusters in patients 6 years of age and older

patient assistance program supports eligible patients who have no health

Co-pay program
for VALTOCO helps commercial patients lower their out-of-pocket costs to as low
as $20

Neurelis, Inc., today announced that insurers
and managed care plans now provide coverage for more than 176 million lives for
the company’s lead product, VALTOCO® (diazepam nasal spray). VALTOCO was
approved by the U.S. Food and Drug Administration (FDA) on January 10, 2020,
for the acute treatment of intermittent, stereotypic episodes of frequent
seizure activity (i.e., seizure clusters, acute repetitive seizures) that are
distinct from a patient’s usual seizure pattern in adult and pediatric patients
6 years of age and older.

“It is a very positive signal that insurers
are quickly providing coverage for VALTOCO,” said Chuck DeWildt, the
company’s Chief Commercial Officer. “We’ve accomplished in just over four
months what takes many companies up to a year to do. I’d like to commend our
market access team and the payers for understanding that this is a large unmet
need for people with epilepsy and we look forward to even more lives being
covered in the coming months to provide this important product to the people
who need it.”

DeWildt added that Neurelis has initiated a
patient assistance program to support eligible patients who do not have access
to insurance. In addition, he said, the company’s co-pay plan has been able to
help eligible commercial insurance patients to pay as little as $20 for
VALTOCO. “These plans take on even more importance at a time when the
COVID-19 pandemic has economically hurt so many people, including those in the
epilepsy community,” DeWildt said.

One other important program initiated by the
company is myNEURELIS?. myNEURELIS provides individualized support for VALTOCO
patients, including access to nurse educators, insurance coverage checks,
financial assistance for those who need it, and more.

The original website link: